The results indicate that add-on treatment with an MRA in patients with hypertension and DM who do not achieve SBP<130 mm Hg with an ACE inhibitor and/or an ARB provides further benefits for BP and UACR and/or UAER. This evidence concerns the gene ACE and hypertensive disorder.